Phase II study of uracil-tegafur plus cisplatin in patients with previously untreated advanced non-small cell lung cancer

Koichi Takayama, Masayuki Kawasaki, Kiyoshi Ninomiya, Akira Motohiro, Masaki Fujita, Kentaro Watanabe, Akira Kajiki, Fumiyuki Iwami, Naoki Miyazaki, Miiru Izumi, Nobuyuki Hara, Yoichi Nakanishi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background and objective: A multi-institutional phase II trial combining uracil-tegafur (UFT) and cisplatin (CDDP) was conducted in patients with previously untreated advanced non-small cell lung cancer (NSCLC) to evaluate the safety and efficacy of this combined treatment regimen. Methods: The entry criteria for this study were previously untreated NSCLC, measurable disease, age <80 years, performance status <2, and adequate haematological, hepatic and renal function. Patients were treated with 400 mg/m2 oral UFT from day 1 to day 14 and 80 mg/m2 cisplatin on day 15. The treatment course was repeated every 3 weeks. Results: Of the 68 patients enrolled, 64 (27 with stage IIIB and 37 with stage IV disease) were eligible for treatment. Twenty of the 64 patients responded to the chemotherapy (response rate 31.3%; 95% CI 21.2-43.4%). The median survival time was 8.6 months, and the 1-year survival was 41.5%. Haematological toxicity ≥WHO grade 3 was seen in 3 (4.7%) patients. For non-haematological toxicities, anorexia with WHO grade 3 was seen in 8 (12.5%) patients, nausea and vomiting with WHO grade 3 in 4 (6.3%), diarrhoea with WHO grade 4 in 1 (1.6%), and liver dysfunction with WHO grade 4 in 1 (1.6%) patient. Conclusions: The combination of oral UFT plus cisplatin was found to be a safe and active treatment against advanced NSCLC. The observed low toxicity of this combined regimen may warrant its application to the treatment of elderly patients.

Original languageEnglish
Pages (from-to)103-107
Number of pages5
JournalRespirology
Volume13
Issue number1
DOIs
Publication statusPublished - Jan 2008

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Phase II study of uracil-tegafur plus cisplatin in patients with previously untreated advanced non-small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Takayama, K., Kawasaki, M., Ninomiya, K., Motohiro, A., Fujita, M., Watanabe, K., Kajiki, A., Iwami, F., Miyazaki, N., Izumi, M., Hara, N., & Nakanishi, Y. (2008). Phase II study of uracil-tegafur plus cisplatin in patients with previously untreated advanced non-small cell lung cancer. Respirology, 13(1), 103-107. https://doi.org/10.1111/j.1440-1843.2007.01190.x